Virology

病毒学

基本信息

项目摘要

The goals of the VC are to enable, broaden and enhance HIV/AIDS research by providing state-of-the-art BSL-2-3 laboratory facilities and equipment, experienced and dedicated professional staff, education, training, virology-specific research materials and assays and protein expression capabilities, all to support multidisciplinary, investigator-initiated basic and clinical HIV/AIDS research. Each of our specific aims represent significant value-added to HIV/AIDS research and the overall CFAR mission as they (i) enable live HIV research among all UAB investigators, (ii) foster the development of HIV/AIDS research by new investigators, (iii) broaden the research capabilities among CFAR faculty, and (iv) encourage research that is translational and multidisciplinary in nature. The services of VC are integral to the AIDS Center as they provide critical support to numerous multidisciplinary basic and clinical HIV/AIDS research programs. The specific aims for the VC are as follows: 1. To provide and maintain state-of-the-art BSL 2-3 laboratory facilities that are necessary to conduct "live" HIV research. 2. To provide safety education and training, and ongoing supervision for all faculty and staff that work in the BSL 2-3 Laboratory. 3. To augment AIDS research capabilities through consultation, assay-specific training, and provision of standardized assays and defined molecular and virologic reagents. 4. To develop specialized genetically engineered tools and assays, including cell lines and viral vectors, to help address new and important investigative challenges in HIV/AIDS research. 5. To continue to offer CFAR investigators the molecular biology services, reagents, and training, that allow a rapid progression from cloning of genes to structure and/or function studies of the gene product. This renewal application reflects important changes that have occurred in the academic HIV/AIDS environment nationally and at UAB since this grant was last competitively renewed. The critical services of two cores that were previously operated independently, the Central Virus Culture Core and the Molecular Biology Core, have been combined into a single core that is now referred to as the Virology Core (VC). This strategy is based on similarities in the nature of virology services offered by the two previous cores and is meant to ensure that we are able to retain and continue to provide critical value-added services, while maximizing proficient utilization of precious CFAR resources.
VC的目标是通过提供最先进的BSL-2-3来促进、扩大和加强艾滋病毒/艾滋病研究 实验室设施和设备,经验丰富和敬业的专业人员,教育,培训,病毒学特定 研究材料和分析以及蛋白质表达能力,所有这些都是为了支持多学科, 艾滋病毒/艾滋病基础和临床研究。我们的每一项具体目标都对艾滋病毒/艾滋病工作具有重要的增值作用 研究和总体CFAR使命,因为它们(i)使所有UAB调查人员能够进行现场艾滋病毒研究,(ii)促进 由新的研究人员开展艾滋病毒/艾滋病研究,㈢扩大CFAR教员的研究能力, 及(iv)鼓励转化及多学科性质的研究。VC的服务是不可或缺的, 艾滋病中心,因为他们为许多多学科的基础和临床艾滋病毒/艾滋病研究提供关键支持 程序.《维也纳公约》的具体目标如下: 1.提供和维护最先进的BSL 2-3实验室设施, “活的”艾滋病毒研究。 2.提供安全教育和培训,并持续监督所有教职员工的工作, BSL 2-3实验室 3.通过咨询、化验具体培训和提供 标准化检测和确定的分子和病毒学试剂。 4.开发专门的基因工程工具和检测方法,包括细胞系和病毒载体, 帮助解决艾滋病毒/艾滋病研究中新的重要调查挑战。 5.为了继续为CFAR研究人员提供分子生物学服务,试剂和培训, 允许从基因克隆到基因的结构和/或功能研究的快速进展 产品 这一更新申请反映了艾滋病毒/艾滋病学术环境发生的重要变化 自上次竞争性更新以来,全国和UAB。两个核心的关键服务, 以前独立运作的中央病毒培养核心和分子生物学核心, 合并成一个单一的核心,现在被称为病毒学核心(VC)。这一战略基于以下方面的相似性: 前两个核心提供的病毒学服务的性质,旨在确保我们能够保留和 继续提供关键的增值服务,同时最大限度地有效利用宝贵的CFAR资源。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JOHN Christopher KAPPES其他文献

JOHN Christopher KAPPES的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JOHN Christopher KAPPES', 18)}}的其他基金

The effects of masculinizing gender-affirming hormone therapy for transgender men on susceptibility to HIV-1 infection modelled ex vivo in cervical mucosal tissue
跨性别男性男性化性别肯定激素治疗对子宫颈粘膜组织离体 HIV-1 感染易感性的影响
  • 批准号:
    10748946
  • 财政年份:
    2023
  • 资助金额:
    $ 18.6万
  • 项目类别:
Elucidating mechanisms of HIV-1 mucosal transmission
阐明 HIV-1 粘膜传播机制
  • 批准号:
    10553626
  • 财政年份:
    2020
  • 资助金额:
    $ 18.6万
  • 项目类别:
Elucidating mechanisms of HIV-1 mucosal transmission
阐明 HIV-1 粘膜传播机制
  • 批准号:
    10428455
  • 财政年份:
    2020
  • 资助金额:
    $ 18.6万
  • 项目类别:
Elucidating mechanisms of HIV-1 mucosal transmission
阐明 HIV-1 粘膜传播机制
  • 批准号:
    9892706
  • 财政年份:
    2020
  • 资助金额:
    $ 18.6万
  • 项目类别:
Analysis of human uterine mucosal cells as targets of HIV-1 infection
人类子宫粘膜细胞作为 HIV-1 感染靶点的分析
  • 批准号:
    8925576
  • 财政年份:
    2015
  • 资助金额:
    $ 18.6万
  • 项目类别:
Virology
病毒学
  • 批准号:
    7697009
  • 财政年份:
    2008
  • 资助金额:
    $ 18.6万
  • 项目类别:
Single cycle reporter assay for quantifying HIV-1 Nab
用于量化 HIV-1 Nab 的单循环报告基因检测
  • 批准号:
    6694007
  • 财政年份:
    2003
  • 资助金额:
    $ 18.6万
  • 项目类别:
CORE--CENTRAL VIRUS CULTURE
核心--中心病毒培养
  • 批准号:
    6299622
  • 财政年份:
    2000
  • 资助金额:
    $ 18.6万
  • 项目类别:
ANALYSIS OF INTEGRASE IN REVERSE TRANSCRIPTION
逆转录整合酶分析
  • 批准号:
    6511302
  • 财政年份:
    2000
  • 资助金额:
    $ 18.6万
  • 项目类别:
ANALYSIS OF INTEGRASE IN REVERSE TRANSCRIPTION
逆转录整合酶分析
  • 批准号:
    6632295
  • 财政年份:
    2000
  • 资助金额:
    $ 18.6万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 18.6万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 18.6万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 18.6万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 18.6万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 18.6万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 18.6万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 18.6万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 18.6万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 18.6万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6091256
  • 财政年份:
    1991
  • 资助金额:
    $ 18.6万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了